On March 26, the REACH Advanced program introduced the course, "Working Strategically with OTD: helping your PI secure industry funding, protect IP and take their research to the next level."
- July 15, 2013
Paris (France), 15 July 2013 - Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it has initiated a research and development collaboration on novel engineered botulinum toxins with Harvard Medical School (Harvard).Under the terms of the agreement, Ipsen will fund Harvard research for at least three years with the aim to discover, evaluate and develop novel engineered recombinant botulinum toxins for the treatment of serious neurologic diseases.
Tag: Sponsored Research
Page 2 of 2